However, this conclusion was from an isolated study and conflicts with the results of a recent meta-analyses of 14 studies which suggested that both, BRCA1 and BRCA2 mutation status were equal predictors of a better OS rate (pooled HR of 0.65 in BRCA1 mutation carriers and a pooled HR of 0.61 in BRCA2 mutation carriers) in Ovarian Cancer patients [56]. This evidence concerns the gene BRCA2 and ovarian carcinoma.